help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Urban, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Urban, R. J.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 4 1248-1254
Copyright © 1997 by The Endocrine Society

Reproductive Endocrinology

Differential Sex Steroid Negative Feedback Regulation of Pulsatile Follicle-Stimulating Hormone Secretion in Healthy Older Men: Deconvolution Analysis and Steady- State Sex-Steroid Hormone Infusions in Frequently Sampled Healthy Older Individuals1

Johannes D. Veldhuis, Ali Iranmanesh, Eugeniusz Samojlik and Randall J. Urban

Division of Endocrinology, Department of Internal Medicine, University of Virginia Health Sciences Center, National Science Foundation Center for Biological Timing (J.D.V.), Charlottesville, Virginia 22908; the Endocrine Section, Medicine Service, Salem Veterans Affairs Center (A.I.), Salem, Virginia 24153; the Endocrine and Metabolism Laboratory, Department of Medicine, New Jersey School of Medicine and Dentistry (E.S.), Princeton, New Jersey 07039; and the Department of Internal Medicine, University of Texas Medical Branch (R.J.U.), Galveston, Texas 77550

Address all correspondence and requests for reprints to: Dr. Johannes D. Veldhuis, Department of Medicine/Endocrinology & Metabolism, University of Virginia Health Sciences Center, NSF Center for Biological Timing, Box 202, Charlottesville, Virginia 22908.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
The healthy aging male reproductive axis tends to exhibit a progressive decline in serum concentrations of biologically available testosterone with gradual concomitant reciprocal increases in both LH and FSH concentrations. However, relatively little is known about the sex steroid-mediated negative feedback regulation of physiologically pulsatile gonadotropin release in general, and episodic FSH release in particular, in older males. To examine the steroid hormone negative feedback control of pulsatile FSH secretion in healthy older men, we applied multiparameter deconvolution analysis to serum FSH (immunoradiometric assay) profiles obtained by sampling every 10 min over 24 h during steady state (4.5-day) infusions of estradiol (E2; 48 µg/day), 5{alpha}-dihydrotestosterone (DHT; 7.0 mg/day), or 5% dextrose in water in five healthy older men, aged 60–73 yr. We observed the following principal responses: 1) both E2 and DHT significantly suppressed mean and 24-h integrated serum FSH concentrations (P < 0.032); 2) the calculated daily secretion rate of FSH fell significantly in all five individuals during DHT infusion; 3) the apparent half-life of FSH decreased during E2 (but not DHT) infusion; 4) DHT infusion reduced the mass and frequency of FSH secretory bursts significantly; 5) neither E2 nor DHT treatment significantly attenuated the release of FSH stimulated by consecutive iv injections of GnRH (10 and 100 µg); and 6) integrated 24-h serum LH (immunoradiometric assay) concentrations decreased significantly during both DHT and E2 infusions, whereas mean LH release after the serial GnRH injections was not altered. Compared to younger men studied earlier in an identical fashion, older men had significantly reduced FSH intersecretory burst intervals, reflecting a higher FSH pulse frequency at baseline and during the steroid infusions and a significantly lower mass of FSH secreted per burst during E2 infusion.

We conclude that healthy older men maintain intact negative feedback responsiveness of the hypothalamo-pituitary gonadotroph unit to exogenously delivered sex steroid hormones, and that individual sex steroid hormones differentially regulate specific features of pulsatile FSH release and half-life in older men.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
SEX STEROID hormones feed back negatively on the hypothalamo-pituitary-gonadotroph unit to regulate the pulsatile secretion of biologically active LH and FSH (1, 2, 3, 4, 5, 6, 7). FSH is not so well studied as LH, but a pulsatile mode of FSH release can be inferred by RIA, immunoradiometric assay (IRMA), immunofluorometric assay, and bioassay in children and young adults (1, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20).

Although FSH is required in man for quantitatively normal spermatogenesis (21), relatively little is known about FSH’s regulated secretion in the human. Continuous short term iv infusions of estrogen or androgen will suppress mean serum immunoreactive FSH concentrations (13, 22), as do depot injections of testosterone (3, 23, 24, 25, 26, 27, 28, 29, 30, 31). Conversely, nonsteroidal antagonists of estrogen or androgen tend to increase FSH release (1, 32).

Most clinical studies of FSH secretion in men have been carried out in young individuals. To investigate how sex steroid hormones regulate the dynamics of FSH secretion and/or removal in older men, we infused estradiol (E2) or the nonaromatizable androgen, 5{alpha}-dihydrotestosterone (DHT), iv over 4.5 days and evaluated feedback-directed changes in 24-h pulsatile FSH release via a two-site IRMA and deconvolution analysis. Results in healthy older individuals were compared with earlier data obtained in an identical fashion in young men (13).


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Patient characteristics

Five men, aged 60–73 yr, participated in this study after providing written informed consent, as approved by the human investigation committee. Each volunteer had normal biochemical tests of hepatic, renal, hematological, and metabolic function. In addition, there was no history of any acute or chronic medical illness, drug or medication use, recent weight loss, undue stress or physical exertion, or recent transmeridian travel in any of the participants. A detailed history and physical examination, including testis size and consistency were unremarkable, and no volunteer described any recent change or abnormality in sexual function. Volunteers also had normal age-specific fasting 0800 h serum concentrations of LH, FSH, T4, TSH, PRL, DHEA, total testosterone, and E2.

Clinical protocol

As described for younger adults (13) and concurrent with the earlier study, older men were studied in the General Clinical Research Center during three separate treatments assigned in randomized order. During each admission, blood sampling was carried out every 10 min for an interval of 28 h, which allowed for a 24-h baseline followed the next morning by two iv injections of GnRH (10 and 100 µg) given 2 h apart. Infusions consisted of 1 L 5% dextrose in water every 12 h containing either DHT (3.5 mg) or 17ß-estradiol (24 µg) for 4.5 days, as previously reported (13). Steady state blood levels of sex steroid hormones were evaluated in 24-h pooled sera.

Hormone assays

Blood samples were allowed to clot at room temperature, and sera were frozen at -20 C for later IRMA of FSH concentrations (Nichols Laboratory, San Juan Capistrano, CA) using a two-site assay standardized according to the Second International Reference Preparation of human menopausal gonadotropin (1, 33, 34, 35). Assay sensitivity was 0.2 IU/L and exhibited negligible (<0.1%) cross-reactivity with LH, hCG, TSH, or free {alpha}-subunit (1, 13, 33, 34, 35). The current mean within- and between-assay coefficients of variation ranged from 5.5–8.7%. All samples were assayed in duplicate, and each 28-h series was assayed within a single run. A dose-dependent (power) variance function was estimated for each set of 169 samples derived from any given sampling session (12, 36) for use as an inverse weighting function in deconvolution analysis (below). Serum concentrations of E2, estrone, DHT, sex hormone-binding globulin (SHBG), and total and free testosterone were measured by RIA (1, 8, 13, 35, 37, 38, 39).

Evaluating FSH secretion and half-life by deconvolution analysis

Each 28-h serum FSH concentration vs. time profile was submitted to deconvolution analysis to estimate the apparent half-life of endogenous FSH, the number of underlying secretory bursts, and their duration, amplitude, and mass via a multiparameter technique (40, 41, 42), here simplified to include purely pulsatile hormone secretion. After the complete series was analyzed for a common FSH half-life and burst half-duration (duration of the calculated secretory event at half-maximal amplitude in minutes), then the 24-h (endogenously driven) FSH pulse amplitude, mass, and frequency and the two 4-h (post-GnRH stimulation) pulses were evaluated separately for statistical purposes. We required 67% confidence interval tests on FSH secretory pulse amplitudes to exceed zero. As approximately 30–45 secretory parameters were estimated from 145 serum FSH concentrations in each time series, the number of statistical degrees of freedom exceeded 100 for the deconvolution fits.

Statistical analysis

To test the null hypothesis that a given steroid hormone infusion neither increased nor decreased any particular measure of FSH secretion or half-life consistently, the binomial distribution was applied. This analysis assumes that individual subjects show statistically independent responses to any given infusion, and the expected treatment responses are dichotomous. Inferences were confirmed by the Wilcoxon signed ranks (paired) test. Data from older and young men studied previously (13) were compared via the Wilcoxon rank sum (unpaired) test. Data are expressed as the mean ± SEM, and statistical significance was construed for P < 0.05.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
As shown in Fig. 1Go, both DHT and E2 infusions significantly suppressed mean 24-h serum FSH concentrations in all five subjects. There were commensurate decreases in integrated serum FSH concentrations (area under the 24-h serum FSH concentration vs. time curve).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 1. Mean 24-h serum FSH concentrations in five older men studied basally during 5% dextrose and water infusion alone (basal) or combined with the nonaromatizable androgen, DHT (7 mg daily) or E2 (48 µg daily) for 4.5 days. After 3.5 days of infusion, blood was sampled at 10-min intervals for 24 h to monitor pulsatile and mean serum FSH concentrations by IRMA (see Materials and Methods). Asterisks denote differences (P < 0.05) vs. basal in the same age group. For comparison, data from younger men studied earlier in an identical manner are also given (14).

 
Deconvolution analysis was used to evaluate the mechanisms by which DHT and E2 reduce mean 24-h serum FSH concentrations in older men. Only DHT infusions significantly suppressed FSH secretory burst frequency, which occurred in all five individuals studied (P < 0.05). The mean ± SEM values for FSH secretory pulse frequency were 19 ± 1 (median, 43) pulses/day at baseline vs. 14 ± 1.7 (median, 11) during DHT infusion (P < 0.05), and 18 ± 2 (median, 2) during E2 delivery. There were corresponding (reciprocal) changes in FSH intersecretory burst intervals (Fig. 2AGo). Older men had consistently (P < 0.05) shorter FSH intersecretory burst intervals during all three infusions compared to those in young men (13).



View larger version (27K):
[in this window]
[in a new window]
  		Figure 2. Upper left, Impact of pure androgen (DHT) or E2 infusions for 4.5 days on deconvolution estimates of FSH intersecretory burst interval (time in minutes separating consecutive release episodes) in older men (hatched bars). DHT reduced the estimated number of FSH secretory episodes in each of the five men studied with concomitant increases in interpulse intervals, whereas E2 did not exert this consistent effect. For comparison, data from younger men (open bars) studied earlier in an identical manner are also given (14). Data are the mean ± SEM. Asterisks denote significant differences vs. baseline corresponding to that age group. Upper right, Androgen (DHT) but not estrogen (E2) infusion over 4.5 days suppressed the FSH secretory burst mass (amount of FSH secreted per burst, international units per L distribution volume). Lower left, Calculated mean daily FSH production rates (international units per L/24 h) in older men infused with 5% dextrose and water alone (basal), the unimpeded androgen (DHT), or E2. Lower right, Calculated FSH half-time of disappearance (minutes) in older men infused with 5% dextrose and water (basal), androgen (DHT), or E2 over 4.5 days.

 
Figure 2BGo demonstrates that DHT infusion significantly suppressed FSH secretory burst mass, which is the calculated amount of FSH (international units) secreted per pulse/L distribution volume. In contrast, E2 did not modify estimated FSH secretory burst mass, although the latter value in older men was significantly lower than that in young men (13). Neither DHT nor E2 affected the calculated secretory burst half-duration, which averaged 8.0 ± 3 (median, 6) min at baseline, 7.5 ± 3 (median, 5.9) min during DHT infusion, and 7.7 ± 2.2 (median, 6.4) min during E2 infusion (P = NS). In contrast, the maximal FSH secretory rate attained within a burst, namely its amplitude, decreased from 0.21 ± 0.06 (median, 0.17) IU/L·min at baseline to 0.16 ± 0.05 (median, 0.11) during DHT infusion and 0.14 ± 0.02 (median, 0.16) IU/L·min during E2 infusion (P < 0.05).

The calculated 24-h endogenous FSH production rate in a model of purely pulsatile hormone secretion is the product of the mass of hormone secreted per burst and the pulse frequency. The mean daily secretion rate of FSH fell significantly during DTH infusion (see Fig. 2CGo).

The estimated half-lives of endogenous FSH averaged 200 ± 30 (median, 200) min basally, 230 ± 12 (median, 240) min during DHT infusion, and 170 ± 11 (median, 170) min during E2 infusion (P < 0.05 for basal vs. E2; Fig. 2DGo).

Figure 3Go illustrates deconvolution-fitted serum FSH concentration profiles over 24 h in one elderly volunteer for each treatment condition. Calculated FSH secretory bursts are depicted also.



View larger version (30K):
[in this window]
[in a new window]
  		Figure 3. Illustrative profiles of serum FSH concentrations (IRMA) observed by sampling blood at 10-min intervals in an individual older man infused with 5% dextrose and water alone (control), E2 (48 µg/day), or DHT (7 mg daily) for 4.5 days. Vertical error bars are within-sample dose-dependent SDs of the assay. The curves through the observed data are predicted by deconvolution analysis assuming a purely pulsatile model of hormone secretion. The right column depicts the calculated FSH secretory events as a function of time. Deconvolution data are summarized in Figs. 1Go and 2Go (and Results) for the group of five subjects as a whole compared to those in young controls.

 
Deconvolution analysis of FSH pulses stimulated by iv injections of 10 and 100 µg GnRH indicated that the mass of FSH secreted was no different for the two doses. Hence, we compared the mean mass of FSH released, which was 4.5 ± 1.0 IU/L at baseline, 6.2 ± 2.0 IU/L during DHT infusion, and 3.0 ± 0.45 IU/L during E2 treatment (P = NS). The corresponding mean (4-h) serum FSH concentrations after GnRH injections were 8.3 ± 2.0, 5.4 ± 2.1, and 4.0 ± 2.1 IU/L, respectively (P = NS). Typical profiles of deconvolution-fitted serum FSH concentration responses to 10 and 100 µg GnRH are illustrated in Fig. 4Go.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 4. Illustrative serum FSH concentrations in response to two consecutive bolus iv injections of GnRH 2 h apart in one healthy older male infused for 4–5 days with vehicle alone (control), E2, or the potent androgen, DHT (see Materials and Methods). The fitted curves (predicted) through the 4 h of 10-min sampled serum FSH measurements (IRMA) are shown in the left column, and the calculated FSH secretory rates over time are shown in the right column.

 
Pooled serum samples from the 145 samples at baseline and separately from the 25 samples after GnRH injections indicated that mean 24-h serum LH concentrations fell from a baseline of 6.1 ± 2.1 to 2.8 ± 0.82 IU/L during DHT infusion and to 4.8 ± 2.2 IU/L during E2 infusion (P < 0.05 for each treatment effect). Mean 4-h serum LH concentrations after GnRH injections were 17 ± 5.1 IU/L (baseline), 18 ± 6.4 IU/L (DHT), and 16 ± 7.7 IU/L (E2; P = NS).

Mean serum sex steroid hormone and SHBG concentrations in older men are shown in Table 1Go. Significant changes were observed as expected during the 4.5-day infusions.


View this table:
[in this window]
[in a new window]
  		Table 1. Impact of 4.5-day estradiol or DHT infusion on serum sex steroid hormone concentrations in older men

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
Although serum FSH concentrations tend to rise progressively with advancing age in healthy men (1, 13, 32, 34, 44, 45, 46, 47), to our knowledge the present study is the first to demonstrate negative feedback actions of (exogenous) androgen and estrogen on pulsatile FSH release and/or the estimated FSH half-life in healthy older men. All five older individuals exhibited sex steroid-induced suppression of 24-h mean serum FSH concentrations by 35–50%, as estimated in a two-site IRMA capable of measuring intact FSH in plasma, which correlates well with our earlier independent in vitro bioassay of FSH by aromatase induction in cultured rat Sertoli or granulosa cells (13, 33).

By deconvolution analysis, we could estimate the relative contributions of pulsatile FSH secretion and FSH half-life to the overall (24-h) serum FSH concentrations. This analysis indicated that in older men pure androgen (DHT) infusion at the daily secretion rate of testosterone suppressed the calculated daily FSH secretion rate by 35–50%. In contrast, E2 diminished the apparent FSH half-life by approximately 50%. Accordingly, androgen and estrogen infusions achieved equivalent suppression of mean serum FSH concentrations in older men, but via distinct mechanisms. Our inference of an increase in FSH clearance (shorter FSH half-life) in response to E2 is consistent with the tendency of basic FSH isoforms to predominate in an estrogen-rich milieu and to exhibit shorter half-lives (2, 48, 49, 50). Conversely, the ability of DHT to decrease FSH secretion rates is consistent with its suppressive effect on LH production rates in older men here and in young individuals studied previously (22, 37, 51).

The nonaromatizable androgen, DHT, reduced total daily FSH secretion via a bipartite mechanism; namely, it significantly decreased (~25–30%) FSH secretory pulse frequency and FSH secretory burst mass. In a simple model of purely pulsatile FSH secretion, the mass of hormone secreted per burst and the number of secretory episodes per day jointly determine the overall secretion rate (40, 52). Thus, the combined inhibitory effects of DHT on FSH secretory burst frequency and mass fully account for the observed 50% fall in mean (24-h) serum FSH concentrations.

In contrast to the ability of E2 to suppress FSH concentrations in older men, this schedule of estrogen infusion did not achieve significant inhibition in the younger population studied previously (13). On the other hand, the present observations in older individuals, that E2 shortens the FSH half-life and that DHT reduces the mass of FSH secreted per burst, are consistent with similar findings in younger men (13). Of note, the DHT-induced decrease in the calculated FSH secretory burst frequency in older subjects recognized here was not observed earlier in six younger individuals, although there was a tendency toward increased interpulse interval length (i.e. decreased FSH pulse frequency) (13). In brief, the inhibitory actions of DHT and E2 in older men are similar to but not identical with those defined in their younger counterparts. Our experiments using a single dose of DTH did not directly test an earlier suggestion that older men may be more susceptible to the negative feedback actions of androgen (7). In addition, whether our inferences in a small healthy cohort of older men apply more generally to older men selected from larger populations without or with concomitant diseases, such as primary gonadal failure, and/or concurrent medication use cannot be determined from our experiments.

Comparison of measures of pulsatile FSH secretion in older men with values in young men studied earlier in an identical manner (13) showed that FSH intersecretory burst intervals were consistently shorter in older men, indicating an increased FSH pulse frequency basally as well as after sex steroid hormone infusion. Recently, using 2.5-min sampling overnight in a separate group of older and young men (53), we identified a significantly higher LH (IRMA) pulse frequency (albeit with lower mean amplitude) in the older cohort. In addition, the older men studied here exhibited a significantly lower FSH secretory burst mass during E2 infusion compared to their younger counterparts (13). As serum E2 concentrations during the infusions were comparable in the two age groups [~60–65 pg/mL (220–240 pmol/L)], and SHBG levels actually rise with age, it is possible that older men are somewhat more sensitive to feedback inhibition by this amount of exogenous estrogen. Our data do not include free E2 levels or address this possibility directly. In contrast, young and older men manifested similar FSH responses to antiestrogen treatment to (partially) antagonize endogenous E2 action (1).

Although our studies do not exclude age-related differences in the GnRH dose-FSH secretory response curve in vivo, we found preserved exogenous GnRH actions during short term infusions of sex steroids (administered at doses that suppress serum FSH concentrations by 35–50%). However, we have not yet examined the dispersion of biochemical FSH isoforms in various sex steroid milieus in young and older men, as observed recently within the changing estrogen milieu of the normal menstrual cycle (2). Lastly, as in young men studied previously, older men showed no difference in the mass of FSH released after iv injection of 10 vs. 100 µg GnRH. This agrees with our more recent detailed GnRH dose-FSH secretory response studies in approximately 20 healthy young and older men showing near-maximal FSH (and LH and {alpha}-subunit) release at a 10-µg dose of GnRH (34).

Endogenous FSH half-lives calculated earlier in young (221 ± 36 min) and older men (220 ± 30 min) (1, 13, 34) agree well with values estimated here (200 ± 30 min) as well as those determined directly by IRMA and bioassay of injected FSH decay curves in hypopituitary men, namely 287 ± 13 min (33). Thus, we infer that the deconvolution-estimated half-life of FSH is comparable in young and older men and is modified by E2, but not DHT, infusions over 4.5 days.

Although apparent basal or non-GnRH-dependent FSH release can be observed in vitro (14, 54, 55) and perhaps in some species in vivo (56), nonpulsatile secretion of FSH is more difficult to evaluate in humans in view of its long plasma half-life (above) (12, 33, 57, 58, 59, 60, 61). GnRH antagonists suppress serum FSH concentrations with a delayed time course and to a lesser final degree than LH (62, 63, 64, 65), consistent with differences in LH/FSH kinetics as well as unequal dependencies on GnRH (38, 66, 67) and on non-GnRH effectors (4, 68, 69, 70, 71, 72). In addition to biological issues, technical considerations make it difficult to simultaneously estimate basal and pulsatile release of a hormone with a prolonged half-life (42, 73, 74), although maximal rates of basal secretion can be estimated for hormones with shorter half-lives, for example testosterone, {alpha}-subunit, insulin, GH, and PTH (34, 43, 53, 75, 76). Thus, here we accepted the provisional assumption of a predominantly pulsatile mode of FSH secretion to allow comparisons with earlier studies in young men (1, 13, 34, 40). A simplifying assumption of negligible basal (interpulse) FSH secretion would predispose to an overestimated half-life and/or pulse mass in the event that substantial basal hormone release was present (42, 74).


   Footnotes
 
1 This work was supported in part by NIH Grant RR-00847 to the General Clinical Research Center of the University of Virginia; Clinical Associate Physician Award 3-MO1-RR-00847–1493 (to R.J.U.); Biomedical Research Support Grant 5-SO7–55-05431–26 (to R.J.U.); Research Career Development Award 1-K04-HD-00634 (to J.D.V.); Diabetes and Research Training Center Grant P60-AM-22125–05; NIH-supported Clinfo Data Reduction Systems; the NSF Science Center for Biological Timing (to J.D.V.); and P-30 Reproduction Research Center Grant P30-HD-28934–03 from the NICHHD. Back

Received October 24, 1996.

Revised December 18, 1996.

Accepted December 26, 1996.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Urban RJ, Dahl KD, Lippert MC, Veldhuis JD. 1992 Endogenous androgen and estrogen modulate immunoradiometric and bioactive FSH secretion and clearance in young and elderly men. J Androl. 13:579–586.[Abstract/Free Full Text]
  2. Zambrano E, Olivares A, Mendez JP, Guerrero L, Veldhuis JD, Ulloa-Aguirre A. 1995 Dynamics of basal and GnRH-releasable serum FSH charge isoform distribution throughout the menstrual cycle. J Clin Endocrinol Metab. 80:1647–1656.[Abstract/Free Full Text]
  3. Veldhuis JD. 1991 The hypothalamic pituitary-testicular axis. In: Yen SSC, Jaffe RB, eds. Reproductive endocrinology. Philadelphia: Saunders; 409–459.
  4. Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. 1991 A pulsatile GnRH stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology. 128:509–517.[Abstract]
  5. Abeyawardene SA, Plant TM. 1989 Bilateral orchidectomy and concomitant testosterone replacement in the juvenile male rhesus monkey (Macaca malutta) receiving an invariant intravenous gonadotropin-releasing hormone (GnRH) infusion results, as in the hypothalamus lesioned GnRH driven adult male, in a selective hypersecretion of follicle stimulating hormone. Endocrinology. 125:257–259.[Abstract]
  6. Drouin J, Labrie F. 1976 Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology. 98:1528–1534.[Abstract]
  7. Winters SJ, Sherins RJ, Troen P. 1984 The gonadotropin-suppression activity of androgen is increased in elderly men. Metabolism. 33:1052–1059.[CrossRef][Medline]
  8. Veldhuis JD, King JC, Urban RJ, et al. 1987 Operating characteristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 65:929–941.[Abstract]
  9. Veldhuis JD, Iranmanesh A, Clarke I, Kaiser DL, Johnson ML. 1989 Random and non-random coincidence between luteinizing hormone peaks and follicle-stimulating hormone, alpha subunit, prolactin, and gonadotropin-releasing hormone pulsations. J Neuroendocrinol. 1:185–194.
  10. Mauras N, Rogol AD, Veldhuis JD. 1989 Specific, time-dependent actions of low-dose estradiol administration on the episodic release of GH, FSH and LH in prepubertal girls with Turner’s syndrome. J Clin Endocrinol Metab. 69:1053–1058.[Abstract]
  11. Veldhuis JD, Johnson ML, Seneta E. 1991 Analysis of the co-pulsatility of anterior pituitary hormones. J Clin Endocrinol Metab. 73:569–576.[Abstract]
  12. Urban RJ, Johnson ML, Veldhuis JD. 1991 In vivo biological validation and biophysical modeling of the sensitivity and positive accuracy of endocrine peak detection. II. The FSH pulse signal. Endocrinology. 128:2008–2014.[Abstract]
  13. Urban RJ, Dahl KD, Padmanabhan V, Beitins IZ, Veldhuis JD. 1991 Specific regulatory actions of dihydrotestosterone and estradiol on the dynamics of FSH secretion and clearance in man. J Androl. 12:27–35.[Abstract/Free Full Text]
  14. Booth RAJ, Weltman JY, Yankov VI, et al. 1996 Mode of pulsatile FSH secretion in gonadal-hormone sufficient and deficient women. J Clin Endocrinol Metab. 81:3208–3214.[Abstract]
  15. McLeod BJ, Craigon J. 1985 Time series analysis of plasma LH and FSH concentrations as a method of assessing episodic secretion. J Reprod Fertil. 74:575.[Abstract/Free Full Text]
  16. Dunger DB, Matthews DR, Edge JA, Jones J, Preece MA. 1991 Evidence for temporal coupling of growth hormone, prolactin, LH and FSH pulsatility overnight during normal puberty. J Endocrinol. 130:141–149.[Abstract/Free Full Text]
  17. Dunkel L, Alfthan H, Stenman UH, Tapanainen P, Perheentupa J. 1990 Pulsatile secretion of LH and FSH in prepubertal and early pubertal boys revealed by ultrasensitive time-resolved immunofluorometric assay. Pediatr Res. 27:215–219.[Medline]
  18. Backstrom CT, McNeilly AS, Leask RM, Baird DT. 1982 Pulsatile secretion of LH, FSH, prolactin, oestradiol and progesterone during the human menstrual cycle. Clin Endocrinol (Oxf). 16:29–42.[Medline]
  19. Parker DC, Judd HL, Rossmann LG, Yen SSC. 1975 Pubertal sleep-wake patterns of episodic LH, FSH and testosterone release in twin boys. J Clin Endocrinol Metab. 40:1099–1109.[Abstract]
  20. Penny R, Olambiwonnu NO, Frasier SD. 1977 Episodic fluctuations of serum gonadotropins in pre- and post-pubertal girls and boys. J Clin Endocrinol Metab. 45:307–311.[Abstract]
  21. Matsumoto AM, Karpas AE, Bremner WJ. 1986 Chronic human chorionic gonadotropin in normal men: evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man. J Clin Endocrinol Metab. 62:1184–1192.[Abstract]
  22. Santen RJ. 1975 Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in man. J Clin Invest. 56:1555–1563.
  23. Veldhuis JD, Iranmanesh A, Urban RJ. Primary gonadal failure in men selectively increases the mass of follicle stimulating hormone (FSH) secreted per burst. Proc of the 24th Annual Meet of the American Soc of Androl. 1993 (Abstract 27).
  24. Shecker CB, Matsumoto AM, Bremner WJ. 1989 Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary. J Clin Endocrinol Metab. 68:397–401.[Abstract]
  25. Hassing JM, Padmanabhan V, Kelch RP, et al. 1990 Differential regulation of serum immunoreactive luteinizing hormone and bioactive follicle-stimulating hormone by testosterone in early pubertal boys. J Clin Endocrinol Metab. 70:1082–1089.[Abstract]
  26. Valk TW, Corley KP, Kelch RP, Marshall JC. 1981 Pulsatile gonadotropin releasing hormone in gonadotropin deficient and normal men: suppression of follilce-stimulating hormone responses by testosterone. J Clin Endocrinol Metab. 53:184–191.[Medline]
  27. Capell PT, Paulsen CA, Derleth D, Skoglund R, Plymate S. 1973 The effect of short-term testosterone administration on serum FSH, LH and testosterone levels: evidence for selective abnormality in LH control in patients with Klinefelter’s syndrome. J Clin Endocrinol Metab. 37:752–760.[Medline]
  28. Winters SJ. 1994 FSH is produced by GnRH-deficient men and is suppressed by testosterone. J Androl. 15:216–219.[Abstract/Free Full Text]
  29. Matsumoto AM. 1990 Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 70:282–286.[Abstract]
  30. Bagatell CJ, Dahl KD, Bremner WJ. 1994 The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl. 15:15–21.[Abstract/Free Full Text]
  31. Sherins RJ, Loriaux DL. 1973 Studies on the role of sex steroids in the feedback control of FSH concentrations in men. J Clin Endocrinol Metab. 36:886–893.[Medline]
  32. Tenover JS, Dahl KD, Hsueh AJ, Lim P, Matsumoto AM, Bremner WJ. 1987 Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men. J Clin Endocrinol Metab. 64:1103–1108.[Abstract]
  33. Urban RJ, Padmanabhan V, Beitins I, Veldhuis JD. 1991 Metabolic clearance of human follicle-stimulating hormone assessed by radioimmunoassay, immunoradiometric assay, and in vitro Sertoli cell bioassay. J Clin Endocrinol Metab. 73:818–823.[Abstract]
  34. Zwart AD, Urban RJ, Odell WD, Veldhuis JD. 1996 Contrasts in the gonadotropin-releasing dose-response relationships for luteinizing hormone, follicle-stimulating hormone, and {alpha}-subunit release in young vs. older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis. Eur J Endocrinol. 135:399–406.[Abstract/Free Full Text]
  35. Reyes Fuentes A, Chavarria ME, Carrera A, et al. 1996 Combined alterations in pulsatile LH and FSH secretion in idiopathic oligospermic men: assessment by deconvolution analysis. J Clin Endocrinol Metab. 81:524–529.[Abstract]
  36. Urban RJ, Evans WS, Rogol AD, Kaiser DL, Johnson ML, Veldhuis JD. 1988 Contemporary aspects of discrete peak detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men. Endocr Rev. 9:3–37.[CrossRef][Medline]
  37. Veldhuis JD, Rogol AD, Samojlik E, Ertel N. 1984 Role of endogenous opiates in the expression of negative feedback actions of estrogen and androgen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest. 74:47–55.
  38. Veldhuis JD, Evans WS, Rogol AD, Kolp L, Thorner MO, Stumpf P. 1986 The pituitary self-priming actions of gonadotropin-releasing hormone: kinetics of estradiol’s potentiating effects on GnRH-facilitated LH and FSH release in healthy post-menopausal women. J Clin Invest. 77:1849–1856.
  39. Veldhuis JD, Wilkowski MJ, Urban RJ, Lizarralde G, Iranmanesh A, Bolton WK. 1993 Evidence for attenuation of hypothalamic GnRH impulse strength with preservation of gonadotropin-releasing hormone (GnRH) pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab. 76:648–654.[Abstract]
  40. Veldhuis JD, Carlson ML, Johnson ML. 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA. 84:7686–7690.[Abstract/Free Full Text]
  41. Veldhuis JD, Johnson ML. 1992 Deconvolution analysis of hormone data. Methods Enzymol. 210:539–575.[Medline]
  42. Veldhuis JD, Johnson ML. 1995 Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data. Methods Neurosci. 28:25–92.
  43. Samuels MH, Veldhuis JD, Cawley C, et al. 1993 Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab. 76:399–403.[Abstract]
  44. Urban RJ, Veldhuis JD. 1988 Hypothalamo-pituitary concomitants of aging. In: Sowers JR, Felicetta JV, eds. The endocrinology of aging. New York: Raven Press; 41–74.
  45. Harman SM, Tsitouras PD, Costa PT, Blackman MR. 1982 Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 54:547–551.[Abstract]
  46. Tenover JS, McLachlan RI, Dahl KD, Burger HG, de Kretser DM, Bremner WJ. 1988 Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab. 67:455–461.[Abstract]
  47. Winters SJ, Troen P. 1982 Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab. 55:560–565.[Abstract]
  48. Wide L, Wide M. 1984 Higher plasma disappearance rate in the mouse for pituitary follicle-stimulating hormone of the young women compared to that of men and elderly women. J Clin Endocrinol Metab. 54:426–429.
  49. Wide L. 1986 The regulation of metabolic clearance rate of human FSH in mice by variation of the molecular structure of the hormone. Acta Endocrinol (Copenh). 112:336–344.[Abstract/Free Full Text]
  50. Ulloa-Aguirre A, Coutifaris C. 1983 Biosynthesis and secretion of follicle-stimulating hormone. Endocr Rev. 4:179–211.[CrossRef][Medline]
  51. Veldhuis JD, Urban RJ, Beitins I, Blizzard RM, Johnson ML, Dufau ML. 1989 Pathophysiological features of the pulsatile secretion of biologically active luteinizing hormone in man. J Steroid Biochem. 33:739–750.[CrossRef][Medline]
  52. Veldhuis JD, Lassiter AB, Johnson ML. 1990 Operating behavior of dual or multiple endocrine pulse generators. Am J Physiol 259:E351–E361.
  53. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. 1995 Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: possible Leydig cell desensitization to endogenous LH signaling–a clinical research center study. J Clin Endocrinol Metab. 80:3025–3031.[Abstract/Free Full Text]
  54. Kotsuji F, Winters SJ, Attardi B, Keeping HS, Oshima H, Troen P. 1988 Effects of gonadal steroids on gonadotropin secretion in males: studies with perifused rat pituitary cells. Endocrinology. 123:2683–2689.[Abstract]
  55. Farnworth PG. 1995 Gonadotropin secretion revisited. How many ways can FSH leave a gonadotroph? J Endocrinol. 145:387–395.[Abstract/Free Full Text]
  56. Alexander SL, Irvine CHG. 1987 Secretion rates and short-term patterns of gonadotropin-releasing hormone, FSH and LH throughout the preovulatory period in the mare. J Endocrinol. 114:351–362.[Abstract/Free Full Text]
  57. Veldhuis JD, Fraioli F, Rogol AD, Dufau ML. 1986 Metabolic clearance of biologically active luteinizing hormone in man. J Clin Invest. 77:1122–1128.
  58. Pepperell RJ, de Kretser DM, Burger HG. 1975 Studies on the metabolic clearance rate and production rate of human luteinizing hormone and on the initial half-life of its subunits in man. J Clin Invest. 56:118–126.
  59. Yen SS, Llerena LA, Pearson OH, Littell AS. 1970 Disappearance rates of endogenous follicle-stimulating hormone in serum following surgical hypophysectomy in man. J Clin Endocrinol Metab. 30:325–329.[Medline]
  60. Coble Jr YD, Kohler PO, Cargille CM, Ross GT. 1969 Production rates and metabolic clearance rates of human follicle-stimulating hormone in premenopausal and postmenopausal women. J Clin Invest. 48:359–363.
  61. Amin HK, Hunter WM. 1970 Human pituitary follicle-stimulating hormone: distribution, plasma clearance and urinary excretion as determined by radioimmunoassay. J Endocrinol. 48:307–317.[Abstract/Free Full Text]
  62. Davis MR, Veldhuis JD, Rogol AD, Dufau ML, Catt KJ. 1987 Sustained inhibitory actions of a potent antagonist of gonadotropin-releasing hormone in postmenopausal women. J Clin Endocrinol Metab. 64:1268–1274.[Abstract]
  63. Urban RJ, Pavlou SN, Rivier JE, Vale WW, Dufau ML, Veldhuis JD. 1990 Suppressive actions of a gonadotropin-releasing hormone (GnRH) antagonist on LH, FSH, and prolactin release in estrogen-deficient postmenopausal women. Am J Obstet Gynecol. 162:1255–1260.[Medline]
  64. Kolp LA, Pavlou SN, Urban RJ, Rivier JC, Vale WW, Veldhuis JD. 1992 Abrogation by a potent GnRH antagonist of the estrogen/progesterone-stimulated surge-like release of LH and FSH in postmenopausal women. J Clin Endocrinol Metab. 75:993–997.[Abstract]
  65. Mortola JF, Sathanandan M, Pavlou S. 1989 Suppression of bioactive and immunoassay follicle-stimulating hormone and luteinizing hormone levels by a potent gonadotropin-releasing hormone antagonist: pharmacodynamic studies. Fertil Steril. 51:957–963.[Medline]
  66. Kartun K, Schwartz NB. 1987 Effects of a potent antagonist to gonadotropin-releasing hormone on male rats: luteinizing hormone is suppressed more than follicle-simulating hormone. Biol Reprod. 36:103–108.[Abstract]
  67. Kotsuji F, Winters SJ, keeping HS, Attardi B, Oshima H, Troen P. 1988 Effects of inhibin from primate Sertoli cells on follicle stimulating hormone and luteinizing hormone release by perifused rat pituitary cells. Endocrinology. 122:2796–2802.[Abstract]
  68. McLachlan RI, Dahl KD, Bremner WJ, et al. 1989 Recombinant human activin-A stimulates basal FSH and GnRH-stimulated FSH and LH release in the adult male macaque, Macaca fascicularis. Endocrinology. 125:2787–2789.[Abstract]
  69. Gross KM, Matsumoto AM, Bremner WJ. 1987 Differential control of luteinizing hormone and follicle stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man. J Clin Endocrinol Metab. 64:675–680.[Abstract]
  70. Medhamurthy R, Culler MD, Gay VL, Negro-Vilar A, Plant TM. 1991 Evidence that inhibin plays a major role in the regulation of follicle-stimulating hormone secretion in the fully adult male rhesus monkey (Macaca mulatta). Endocrinology. 129:389–395.[Abstract]
  71. Ying S. 1988 Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of FSH. Endocr Rev. 9:267.[CrossRef][Medline]
  72. Kumar RT, Malcolm LJ. 1995 Hormonal regulation of human follicle-stimulating hormone-B subunit gene expression: GnRH stimulation and GnRH-independent androgen inhibition. Neuroendocrinology. 61:628–637.[Medline]
  73. Johnson ML, Veldhuis JD. 1995 Evolution of deconvolution analysis as a hormone pulse detection method. Methods Neurosci. 28:1–24.
  74. Veldhuis JD, Evans WS, Johnson ML. 1995 Complicating effects of highly correlated model variables on nonlinear least-squares estimates of unique parameter values and their statistical confidence intervals: estimating basal secretion and neurohormone half-life by deconvolution analysis. Methods Neurosci. 28:130–138.[CrossRef]
  75. Veldhuis JD, Liem AY, South S, et al. 1995 Differential impact of age, sex-steroid hormones, and obesity on basal vs. pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 80:3209–3222.[Abstract]
  76. Porksen N, Munn S, Steers J, Veldhuis JD, Butler P. 1995 Impact of sampling technique on appraisal of pulsatile insulin secretion by deconvolution and Cluster analysis. Am J Physiol. 269:E1106–E1114.



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu and R. I. McLachlan
Male Hormonal Contraception: So Near and Yet So Far
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2474 - 2476.
[Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. Aksglaede, R. B. Jensen, E. Carlsen, P. Kok, D. M Keenan, J. Veldhuis, N. E Skakkebaek, and A. Juul
Increased basal and pulsatile secretion of FSH and LH in young men with 47,XXY or 46,XX karyotypes.
Eur. J. Endocrinol., June 1, 2008; 158(6): 803 - 810.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. Franco, J. D Veldhuis, A. Iranmanesh, J. Brandberg, L. Lonn, B. Andersson, B.-A. Bengtsson, J. Svensson, and G. Johannsson
Thigh intermuscular fat is inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity.
Eur. J. Endocrinol., August 1, 2006; 155(2): 261 - 268.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Hestiantoro and D. F. Swaab
Changes in Estrogen Receptor-{alpha} and -{beta} in the Infundibular Nucleus of the Human Hypothalamus Are Related to the Occurrence of Alzheimer's Disease Neuropathology
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1912 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
A. M. Matsumoto
Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. A. Schnorr, M. J. Bray, and J. D. Veldhuis
Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, Ali Iranmanesh, Thomas Mulligan, and Steven M. Pincus
Disruption of the Young-Adult Synchrony between Luteinizing Hormone Release and Oscillations in Follicle-Stimulating Hormone, Prolactin, and Nocturnal Penile Tumescence (NPT) in Healthy Older Men
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3498 - 3505.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, A. Iranmanesh, L. M. Demers, and T. Mulligan
Joint Basal and Pulsatile Hypersecretory Mechanisms Drive the Monotropic Follicle-Stimulating Hormone (FSH) Elevation in Healthy Older Men: Concurrent Preservation of the Orderliness of the FSH Release Process: A General Clinical Research Center Study
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3506 - 3514.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Vernet, J. J. Bonavera, R. S. Swerdloff, N. F. Gonzalez-Cadavid, and C. Wang
Spontaneous Expression of Inducible Nitric Oxide Synthase in the Hypothalamus and Other Brain Regions of Aging Rats
Endocrinology, July 1, 1998; 139(7): 3254 - 3261.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bergendahl, J. A. Aloi, A. Iranmanesh, T. M. Mulligan, and J. D. Veldhuis
Fasting Suppresses Pulsatile Luteinizing Hormone (LH) Secretion and Enhances Orderliness of LH Release in Young but Not Older Men
J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1967 - 1975.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Urban, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Urban, R. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.